Moreover, it can affect the expression of SREBP‐1 in the nucleus through the PI3K/AKT/mTOR pathway, and consequently influence the expression of downstream lipogenesis genes such as SCD1 and ACC, thus achieving the purpose of treating hyperlipidemia. The gene discussed is MTOR; the disease is hyperlipidemia.